Results 211 to 220 of about 105,344 (245)
Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes. [PDF]
Front Med (Lausanne)Lv S, Wang J, Chen G, Wang Y, Liu N.
europepmc +1 more source
Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells. [PDF]
Curr OncolAltun G, Yönem Ö.
europepmc +1 more source
Metastatic Tumors from Unknown Primary in Cervical Lymph Nodes: A Decade of Study in a Tertiary Care Center of a Resource-Limited Country. [PDF]
JNMA J Nepal Med AssocKafle S.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Oncology, 2010
Medullary thyroid carcinoma (MTC) accounts for 5-8% of all thyroid cancers. MTC is mainly sporadic in nature, but an hereditary pattern [multiple endocrine neoplasia type 2 (MEN 2)] is present in 20-30% of cases, transmitted as an autosomal-dominant trait due to germline mutations of the RET proto-oncogene.
Pacini F. +3 more
openaire +3 more sources
Medullary thyroid carcinoma (MTC) accounts for 5-8% of all thyroid cancers. MTC is mainly sporadic in nature, but an hereditary pattern [multiple endocrine neoplasia type 2 (MEN 2)] is present in 20-30% of cases, transmitted as an autosomal-dominant trait due to germline mutations of the RET proto-oncogene.
Pacini F. +3 more
openaire +3 more sources
Hematology/Oncology Clinics of North America, 2007
Medullary thyroid carcinoma is a neuroendocrine tumor derived from the C cells of the thyroid gland and accounts for approximately 5% of all thyroid carcinomas. Approximately 30% of the cases are associated with an autosomal dominant syndrome called multiple endocrine neoplasia type 2, and the identification of these individuals is important because ...
Ana O, Hoff, Paulo M, Hoff
openaire +2 more sources
Medullary thyroid carcinoma is a neuroendocrine tumor derived from the C cells of the thyroid gland and accounts for approximately 5% of all thyroid carcinomas. Approximately 30% of the cases are associated with an autosomal dominant syndrome called multiple endocrine neoplasia type 2, and the identification of these individuals is important because ...
Ana O, Hoff, Paulo M, Hoff
openaire +2 more sources
Endocrine Practice, 2013
This review outlines advances in the diagnosis, genetic testing, and progress in medullary thyroid cancer (MTC) treatment in light of the most recent evidence.English-language articles pertaining to MTC published up to 2012 were reviewed. The pertinent articles and their references were obtained and those considered relevant were reviewed for inclusion.
Marcio L, Griebeler +2 more
openaire +2 more sources
This review outlines advances in the diagnosis, genetic testing, and progress in medullary thyroid cancer (MTC) treatment in light of the most recent evidence.English-language articles pertaining to MTC published up to 2012 were reviewed. The pertinent articles and their references were obtained and those considered relevant were reviewed for inclusion.
Marcio L, Griebeler +2 more
openaire +2 more sources